Press Releases

Date Title and Summary View
Toggle Summary Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
NORCROSS, Ga. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have received notice of issuance of U.S.
View HTML
Toggle Summary Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
NORCROSS, Ga. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019 .
View HTML
Toggle Summary Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
NORCROSS, Ga. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated
View HTML
Toggle Summary Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
NORCROSS, Ga. , May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering has closed.  The Rights Offering resulted in the issuance of approximately 10.4 million shares of the
View HTML
Toggle Summary Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
NORCROSS, Ga. , May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights
View HTML
Toggle Summary Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
NORCROSS, Ga. , May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein .  The letter reads as follows: Dear Fellow
View HTML
Toggle Summary Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29.  Rights expire at 5:00 PM Eastern on May 23, 2019 Portion of the Net Proceeds of Rights Offering to be used for Phase 3 clinical trial of belapectin,
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
NORCROSS, Ga. , April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key dates and pricing structure for its previously announced rights offering of approximately 14 million
View HTML
Toggle Summary Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga. , April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s President and Chief Executive Officer, will present at the H.C.
View HTML
Toggle Summary Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
NORCROSS, Ga. , March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination
View HTML